Eli Lilly's new weight-loss pill, Foundayo, was prescribed 7,335 times in the U.S. in the fourth week, a modest uptake ...
Quarterly results important but investors eye future growth Novo's internal shake-up affects investor confidence Zepbound maintains U.S. market lead over Wegovy Lilly has the edge on Danish rival Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results